Fadi H. Mourad

Prof. Fadi H. Mourad

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
WCWebber Pak Wo Chan
Webber Pak Wo Chan
FMFadi H. Mourad
Fadi H. Mourad
RLRupert Leong
Rupert Leong
Crohn's disease (CD) is a chronic relapsing and remitting disease that can affect any segments of the gastrointestinal tract. More than 50% of patients with CD develop stricturing or penetrating complications within the first 10 years after diagnosis. Strictures can lead to intestinal obstruction, which is a common indication for surgery. Despite significant advances in the understanding of the pathogenesis of intestinal fibrostenosis, imaging and therapeutic armamentarium of CD, the risk of intestinal surgery remained significantly high. Endoscopic balloon dilation is a promising first‐line alternative to surgery as it is less invasive and could preserve intestinal length. In this review, we will evaluate the literature on the mechanism of intestinal fibrosis, emerging imaging techniques, and management strategies for CD associated strictures.

27 February 2020 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
FMFadi H. Mourad
Fadi H. Mourad
JHJana G Hashash
Jana G Hashash
VKViraj C Kariyawasam
Viraj C Kariyawasam
RLRupert W Leong
Rupert W Leong
Despite multiple studies, the role of cytomegalovirus [CMV] infection in exacerbating the severity of inflammation in ulcerative colitis [UC], and its response to treatment, remain debatable. Additionally, the optimal diagnostic tests for CMV infection in the setting of UC relapse, and timing of antiviral treatment initiation, remain unclear. The challenge faced by gastroenterologists is to differentiate between an acute UC flare and true CMV colitis. It seems that the presence of CMV colitis, as defined by the presence of intranuclear or intracellular inclusion bodies on haematoxylin and eosin [H&E] staining and/or positive immunohistochemistry [IHC] assay on histology, is associated with more severe colitis. Patients with CMV infection and acute severe colitis are more resistant to treatment with corticosteroids than non-infected patients. This refractoriness to steroids is related to colonic tissue CMV viral load and number of inclusion bodies [high-grade CMV infection] which may have a pronounced effect on clinical outcomes and colectomy rates. Whereas many studies showed no effect for antiviral treatment on colectomy rates in CMV-infected UC patients, there was a significant difference in colectomy rates of patients with high-grade infection who received anti-viral therapy compared with those who did not receive treatment. It was therefore proposed that high-grade CMV disease indicates that the virus is acting as a pathogen, whereas in those with low-grade CMV disease, the severity of IBD itself is more likely to influence outcome. The different algorithms that have been put forward for the management of patients with UC and concomitant CMV infection are discussed.

1 September 2000 in Gut
Verified
Journal Article
Open access
PDF file
FMFadi H. Mourad
Fadi H. Mourad
CNC F Nassar
C F Nassar
BACKGROUND: The enteric nervous system is important in the pathophysiology of intestinal fluid secretion induced by cholera toxin (CT), Escherichia coli heat labile (LT), and heat stable (STa) toxins. The neurotransmitters involved are not fully elucidated. Vasoactive intestinal polypeptide (VIP), a potent intestinal secretagogue present in the enteric nervous system, is increased after exposure of the cat intestine to CT. Whether VIP is involved in the pathogenesis of cholera and other toxins in not known. AIM: To study in vivo the effect of VIP antagonism on jejunal fluid secretion induced by CT, LT, and STa. METHODS: CT, LT (25 μg), or 0.9% NaCl was instilled in an isolated 25 cm segment of rat jejunum, and the VIP antagonist (VIPa) [4Cl-D-Phe 6 , Leu 17 ]-VIP (0.2 or 2 μg/kg/min) or 0.9% NaCl was given intravenously. Two hours later, single pass in vivo jejunal perfusion was performed to assess fluid movement. In STa experiments, intravenous VIPa or 0.9% NaCl was given and 30 minutes later the jejunal segment was perfused with a solution containing STa 200 μg/l. RESULTS: VIPa had no effect on basal intestinal fluid absorption. CT induced net fluid secretion (median −68 μl/min/g dry intestinal weight (interquartile range −80 to −56)) which was dose dependently reversed by VIPa (6.2 (−16 to 34) and 29 (17 to 42); p<0.01). Similarly, LT induced secretion (−63 (−73 to −30)) was attenuated by VIPa (0.2 μg/kg/min) (−15 (−24 to −1); p<0.01) and totally reversed to normal levels by VIPa (2 μg/kg/min) (37 (28–56); p<0.01 compared with LT and not significant compared with normal controls). STa induced secretion (−17 (−19 to −2)) was also reversed by VIPa (12 (9–23) and 14 (0–26); p<0.01). CONCLUSION: VIP plays an important role in CT, LT, and STa induced intestinal secretion and may be the final putative neurotransmitter in the pathophysiology of these toxins.

1 October 2011 in Progress in Neurobiology
Verified
Journal Article
Closed access
FMFadi H. Mourad
Fadi H. Mourad
NSNayef E. Saadé
Nayef E. Saadé

1 March 2001 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
FMFadi H. Mourad
Fadi H. Mourad
HHHoweida M. Hannoush
Howeida M. Hannoush
MBMajed Bahlawan
Majed Bahlawan
IUImad Uthman
Imad Uthman
SUSuhatl Uthman
Suhatl Uthman
Although rare, panniculitis and polyarthritis can be the presenting manifestations of pancreatitis. Early recognition of this triad is critical because of the high mortality rate from pancreatic disease when the diagnosis is delayed. We report a patient with chronic alcohol intake whose sole presentation was severe polyarthritis and skin lesions secondary to chronic pancreatitis associated with extra pancreatic pseudocyst. Both arthritis and skin lesions disappeared after partial pancreatectomy and pancreatic stent insertion for a pancreatic duct stricture.

22 March 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
FMFadi H. Mourad
Fadi H. Mourad
RLRupert W Leong
Rupert W Leong